Roche is Back as Expected
Long Ideas - Updated at 11:00AM, 12/20/12. Shares of Illumina (ILMN) climbed 7% in the pre-market on news that Roche (RHHBY) may have revised higher its previous buy-out … Continue Reading
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Fundamentals and Technicals Continue to Support QCOR
Long Ideas - Shares of Questcor Pharmaceuticals (NASDAQ:QCOR), despite a large short interest, have continued to perform well for shareholders and broke through several resistance levels this week to … Continue Reading
Read nowONTY Plummets Following Stimuvax Phase III Failure
- Another cancer vaccine fell by the wayside on Wednesday morning, as Oncothyreon (NASDAQ:ONTY) and Merck Serono (NYSE:MRK) announced that a Phase III study for the … Continue Reading
Read nowA Geron Update: Imetelstat Data, Restructuring, and the Road Ahead
- Few investors that choose to invest in the biotechnology sector expect stability. Biotechnology stocks may be insulated from macroeconomic issues, but they are exposed to … Continue Reading
Read nowStudy Supports Use of Non-Opioid Analgesics; Cadence to Benefit from Growing Research
Long Ideas - Pacira Pharmaceuticals (NASDAQ:PCRX) reported on Tuesday morning that, based on the results of a regional health system analysis conducted by Barnabas Health, opioid use in … Continue Reading
Read nowCan Regeneron Continue to Generate Profits?
Long Ideas - For biotechnology investors, a biotechnology company’s “pivot” period, the time frame when it transitions from a development-stage company to a solidly profitable company can often … Continue Reading
Read nowOrexigen: The Best Bet In Obesity for 2013
Long Ideas - Orexigen Therapeutics (OREX) will be the last of three leading weight-loss drug developers to enter the large potential market for new obesity treatments, and biotech … Continue Reading
Read now